Idarucizumab, a monoclonal antibody fragment, was developed to reverse the anticoagulant effect of dabigatran. We performed a multicenter, prospective, open-label study to determine whether 5 g of ...

(Updated) Since the approval of dabigatran (Pradaxa, Boehringer Ingelheim) in Europe in 2008 and in the US in 2010 there have been persistent and lingering concerns about the drug's safety. Now ...

Dabigatran will be sold under the brand name Pradaxa. Analysts are predicting the drug will be a blockbuster, with sales reaching an estimated $2.5 billion annually by 2020.

Compared with controls, dabigatran (Pradaxa) is associated with a higher risk of myocardial infarction (MI) or acute coronary syndrome, according to a new meta-analysis published online in ...

Ascend Laboratories has recalled 10 lots of Dabigatran Etexilate capsules, used to lower the risk of blood clots and strokes, after finding the nitrosamine in the drug was above the FDA’s ...

Bleeding is an expected complication of dabigatran, especially in the elderly, 1,2 a risk that is not completely mitigated by a dose reduction: 22 of our patients had a bleeding episode while ...

Learn why recent studies on the use of dabigatran in patients with atrial fibrillation have suggested a new potential role for dabigatran in patients with mechanical heart valves.

The RE-DUAL PCI™ trial explored anticoagulation with Pradaxa® (dabigatran etexilate) dual therapy without aspirin in non-valvular atrial fibrillation ...

Treatment with the 150-mg twice daily do se of dabigatran is equally safe and effective in patients with permanent, persistent, and paroxysmal atrial fibrillation. The 110-mg dose, however, was ...

Anticoagulation with dabigatran was associated with fewer bleeding complications compared with warfarin among patients undergoing ablation for atrial fibrillation.

In two trials exploring potential new indications, dabigatran (Pradaxa; Boehringer Ingelheim) failed to show significant advantages over standard treatments for embolic stroke of undetermined source ...

Unbeknownst to many physicians, bottles of the new oral anticoagulant dabigatran (Pradaxa) must be used within 30 days of opening, according to information from the manufacturer.